Journal of the American College of Cardiology
-
J. Am. Coll. Cardiol. · Dec 2004
Randomized Controlled Trial Multicenter Study Clinical TrialA randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation.
The purpose of this study was to determine the efficacy and safety of intravenous RSD1235 in terminating recent onset atrial fibrillation (AF). ⋯ RSD1235, a new atrial-selective anti-arrhythmic agent, appears to be efficacious and safe for converting recent onset AF to sinus rhythm.